

Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals Limited held on 14th November, 2022 at 3.00 PM at its Corporate Office at Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223 has approved the Un-audited 1st quarterly Financial Statements of the Company for the period ended 30th September, 2022 and has decided, declared and recommended the following price sensitive information accordingly:

The Board of Directors of the Company declared the following financial information:

1) Financial Information:

- a. Earning Per Share (EPS) : Tk. 0.99
- b. Net Asset Value Per Share (NAVPS) : Tk. 26.72
- c. Net Operating Cash Flow Per Share (NOCFPS) : Tk. 0.03

2) Comparative Statement of Financial Information:

Sl. No.	Particulars	30 th Sept'22	30 th Sept'21
1	Earning Per Share (EPS)	Tk. 0.99	Tk. 1.52
2	Net Asset Value Per Share (NAVPS)	Tk. 26.72	Tk. 24.71
3	Net Operating Cash Flow Per Share (NOCFPS)	Tk. 0.03	Tk. (0.65)

Date : 14.11.2022

By order of the Board of Directors



Beacon Business Centre
9/B/2, Toyenbee Circular Road, Motijheel, Dhaka-1223

A handwritten signature in black ink, appearing to read 'Khalilur Rahman', is written over a horizontal line.

Khalilur Rahman FCS
Company Secretary (Acting)